Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Recent & Breaking News (NDAQ:PLUR)

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

Accesswire 11 days ago

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

GlobeNewswire October 28, 2024

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

GlobeNewswire July 18, 2024

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

GlobeNewswire July 8, 2024

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

GlobeNewswire June 18, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

GlobeNewswire June 6, 2024

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

GlobeNewswire May 20, 2024

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

GlobeNewswire May 2, 2024

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

GlobeNewswire April 8, 2024

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

GlobeNewswire March 28, 2024

Pluri Inc. Announces 1-for-8 Reverse Share Split

GlobeNewswire March 27, 2024

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

GlobeNewswire March 21, 2024

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

GlobeNewswire March 19, 2024

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

GlobeNewswire March 14, 2024

Pluri(TM) Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

GlobeNewswire March 11, 2024

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

GlobeNewswire March 6, 2024

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

GlobeNewswire February 28, 2024

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

GlobeNewswire January 23, 2024

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

GlobeNewswire January 8, 2024

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

GlobeNewswire December 21, 2023